


amfAR

MAKING AIDS HISTORY



2017 Annual Report

amfAR, The Foundation for AIDS Research

Contents

amfAR in 2017	01
<hr/>	
Grants, Fellowships, and Awards	07
Research Grants, Fellowships, and Awards	
TREAT Asia Grants and Awards	
GMT Initiative Awards	
Public Policy Awards	
<hr/>	
Financial Highlights	13
<hr/>	
Leadership and Advisory Committees	15
Board of Trustees	
Scientific Advisory Committee	
Program Advisory Council	
Management Group	

**amfAR, The Foundation for AIDS Research,
is dedicated to ending the global AIDS
epidemic through innovative research.**



amfAR CEO Kevin Robert Frost (right) moderates a panel discussion at the amfAR HIV Cure Summit.

Research

Countdown to a Cure for AIDS

In 2015, amfAR announced a \$100 million investment strategy to support its Countdown to a Cure for AIDS initiative, which is aimed at developing the scientific basis for a cure by 2020. The strategy represents an unprecedented expansion of amfAR’s grant making and is designed to provide support to any scientist or team of investigators for any research idea with the potential to advance the search for a cure, at any stage of its development.

amfAR has since awarded 58 Countdown grants totaling more than \$41 million to support research conducted by 222 scientists working at 74 institutions in 10 countries. Structured to provide sustained support for a wide range of studies that advance both emerging and established ideas, the strategy comprises the following components:


- ▶ **The amfAR Institute for HIV Cure Research**, established in 2016 with a \$20 million grant over five years to the University of California, San Francisco (UCSF), is the cornerstone of amfAR’s cure research efforts.
- ▶ **Innovation Grants**, two-year awards of up to \$200,000 each, enable researchers to test innovative ideas supported by limited preliminary data.
- ▶ **Impact Grants** of up to \$2 million each over four years support the in-depth development of concepts already underpinned by preliminary data showing genuine potential for achieving a cure.
- ▶ **Investment Grants** are aimed at recruiting the experience and expertise of scientists from outside the field of HIV. These \$1 million grants are awarded over a four-year period. Grantees may have expertise in fields such as cancer, neuroscience, or inflammatory disease that can directly inform efforts to cure HIV.

- ▶ **ARCHE**, the amfAR Research Consortium on HIV Eradication, was launched in 2010. It supports collaborative teams of scientists in the U.S. and around the world working on a range of HIV cure strategies.
- ▶ **The Opportunity Fund** is a funding mechanism that enables amfAR to respond quickly to emerging and unforeseen research opportunities.

HIV Cure Summit

In December 2016, amfAR held its third annual HIV Cure Summit at UCSF. Leading amfAR-funded cure researchers detailed their progress and discussed the scientific challenges that continue to stand in the way of a cure. Drs. Peter Hunt, Warner Greene, Satish Pillai, and Steve Deeks reported on their efforts to pinpoint and

measure the size of latent HIV reservoirs; shock the virus out of hiding so it can be killed; and test interventions developed by Institute researchers in clinical trials.



amfAR grantee Dr. Benjamin Burwitz of Oregon Health and Science University


Innovation Grants

In July 2017, amfAR awarded \$1.2 million in Innovation grants to six researchers exploring mechanisms of HIV persistence and the potential for viral eradication. Among the grantees were Dr. Joshua Schiffer, from Fred Hutchinson Cancer Research

Center in Seattle, who is testing a drug normally used to prevent organ transplant rejection for its potential to eliminate the reservoir completely; Drs. Andrew Henderson, from Boston University School of Medicine, and Fabio Romerio, from the University of Maryland in Baltimore, who are exploring a cure strategy known as “block and lock,” which aims to silence HIV and prevent its re-emergence when therapy is stopped; and Dr. Benjamin Burwitz, from Oregon Health and Science University in Portland, who plans to generate a monkey model lacking the protein CCR5, the primary means by which most types of HIV infect cells.

Investment Grants

In February 2017, amfAR announced a new round of Investment grants totaling \$1.2 million to support six research projects that enlist the help of bioengineers to eradicate the main barrier to a cure: latent HIV reservoirs. One pair of researchers—Dr. Timothy Henrich, of UCSF and the amfAR Institute for HIV Cure Research, and bioengineer Dr. Utkan Demirci from Stanford—aim to apply magnetic levitation of single cells to identify and characterize HIV reservoirs. Another team—Drs. Hui Zhang and Weiming Yang of Johns Hopkins University in Baltimore—is using mass spectrometry to identify molecules on the surface of cells that differentiate latent reservoirs from uninfected cells. And a third—Drs. Priti Kumar and Mark Saltzman of Yale University in New Haven, CT—is exploring a novel gene-editing approach using a cell’s machinery to eliminate HIV reservoirs.



amfAR grantee Dr. Weiming Yang of Johns Hopkins University

ARCHE (amfAR Research Consortium on HIV Eradication)

In July 2017, amfAR awarded more than \$2.3 million in ARCHE grants to seven teams of researchers (see page 7) working on gene therapy-based approaches to curing HIV. The researchers are pursuing projects such as: designing and refining vectors that can accurately target HIV reservoir cells; using CAR T cells, which have shown remarkable promise in curing cancer, to kill HIV-infected cells; and using viral and non-viral delivery mechanisms to deliver genetic scissors to cut the virus out of human DNA.

Mathilde Krim Fellowships

In October 2016, amfAR announced the recipients of the Mathilde Krim Fellowships in Basic Biomedical Research, which support bright young scientists seeking innovative solutions to HIV/AIDS. The six Krim Fellows were each awarded approximately \$150,000 over two years.

Published Research

Research studies make the greatest impact on the HIV field and on the broader scientific community when they are published in scientific journals. In FY2017, 52 scientific publications resulted from amfAR-funded research.

Think Tanks

In October 2016, amfAR hosted a think tank in Lisbon, Portugal, titled, “Progress Report: Research toward a Cure for AIDS in the context of IciStem.” IciStem is a consortium of 17 European researchers that aims to replicate the case of “the Berlin patient,” who remains the only person known to have been cured of HIV. It was created and is funded by amfAR through its Countdown to a Cure for AIDS initiative.

amfAR hosted another think tank in April 2017 in Palo Alto, CA, on strategies to identify latently infected cells. The researchers discussed finding a biomarker for these cells as an alternative approach to “shock and kill.” One of the biggest challenges with the “shock-and-kill” strategy is that current drug regimens do not reawaken all of the infected cells.

HIV Research Summit in Brazil

In March 2017, amfAR hosted an HIV research summit at the University of São Paulo, bringing together 250 community members, medical students, healthcare professionals, and representatives from 10 São Paulo-based nongovernmental organizations. The summit was held in conjunction with the Advanced Course on HIV Pathogenesis at the university’s School of Medicine.

TREAT Asia

amfAR’s TREAT Asia (Therapeutics Research, Education, and AIDS Training in Asia) program is a network of hospitals, clinics, and research institutions working with civil society to ensure the safe and effective delivery of treatments for HIV and its co-infections to adults and children across the Asia-Pacific through research, education, and advocacy of evidence-based HIV-related policies. The TREAT Asia Network encompasses 21 adult and 20 pediatric sites throughout the region, which collaborate on a variety of projects. TREAT Asia scientists produced a record 35 publications in peer-reviewed medical journals in 2017.

Gathering Critical Information

TREAT Asia pioneered the region's first adult observational database for HIV/AIDS—the TREAT Asia HIV Observational Database (TAHOD)—which now includes anonymous data from approximately 9,200 patients at 21 clinical sites in 12 countries. The information gathered in the database informs the development of more effective research and treatment programs and helps define treatment standards specific to HIV/AIDS in Asia. The TAHOD Low-Intensity Transfer (TAHOD-LITE) database, an extension of TAHOD, contains data from over 37,000 HIV-positive patients across 10 TREAT Asia network sites. It aims to increase the scope of adult data collection by gathering a subset of core variables from the entire cohort of HIV-infected patients who have sought care at selected TAHOD sites.

A Global Collaboration

Since 2006, TREAT Asia has managed the Asia-Pacific section of the International epidemiology Databases to Evaluate AIDS (IeDEA), a global collaboration established by the U.S. National Institute of Allergy and Infectious Diseases. In FY2017, the IeDEA consortium funded the second year of STAY (Study of Transitioning Asian Youth), which aims to document the experience of HIV-infected young adults transitioning from pediatric to adult care.

Improving Care for Children

The TREAT Asia Pediatric HIV Observational Database (TApHOD) is a regional pediatric HIV study set up by TREAT Asia in 2006. It was modeled after the adult database and includes data from more than 6,400 children and adolescents at 19 clinical sites in Cambodia, India, Indonesia, Malaysia, Thailand, and Vietnam.

Addressing Adolescent Mental Health

In January 2017, TREAT Asia organized a think tank in Bangkok on adolescent mental health, bringing together regional investigators and youth advocates from Cambodia, Indonesia, Malaysia, Thailand, and Vietnam to discuss gaps in research and clinical training. As a result of the discussion, TREAT Asia is evaluating the prevalence of mental health disorders among HIV-positive adolescents in the

region and developing trainings for pediatric HIV providers. TREAT Asia hosted the first such training in June 2017 in Bangkok to help clinicians better diagnose and manage mental health disorders in adolescents living with HIV. The workshop included more than 30 clinical and mental health professionals who work with HIV-positive youth in Thailand, Cambodia, Indonesia, and Malaysia. Participants reviewed the epidemiology of adolescent mental health issues and discussed mental health needs among youth living with HIV, psychopharmacology, and suicide risk assessment tools.

Empowering Youth Advocates

The first class of TREAT Asia's Youth ACATA—Asia Community for AIDS Treatment and Advocacy—held its final workshop in June 2017 in Bangkok, where eight young people living with HIV from Cambodia, Indonesia, and Thailand graduated from the two-year leadership training program. Launched in 2015 with support from ViiV Healthcare's Positive Action for Adolescents program, Youth ACATA aims to educate participants about HIV and antiretroviral therapy and connect them to other HIV-positive youth in the region.

Helping Adolescents Transition to Adult Care

TREAT Asia continued working to help adolescents living with HIV transition to adult care. With funding from AIDS Life Austria, the program provided a grant to the Children and Youth Program of SEARCH (South East Asia Research Collaboration on HIV) at the Thai Red Cross AIDS Research Centre in Bangkok to implement a transition model that focuses on issues such as moving to adult care, coping with negative emotions, treatment, and stigma.

Advocating for Co-Infection Treatment Access

In June 2017, TREAT Asia held its annual regional advocacy meeting on hepatitis C, HIV, and tuberculosis treatment in Bangkok, with civil society organizations, clinical care professionals, and intellectual property experts. During the year, TREAT Asia also attended and presented at several conferences on hepatitis C treatment access and partnered with civil society groups and funders on advocacy efforts.

Introducing PrEP to the Philippines


Enrollment began in July 2017 for a two-year pilot project that introduced antiretroviral pre-exposure prophylaxis (PrEP) to the Philippines in an effort to curb the rapid spread of HIV infection among men who have sex with men (MSM) and transgender individuals. The project, known as PrEPPY (PrEP Pilipinas), is evaluating community-based, peer-driven delivery of PrEP at two clinics in Manila. amfAR is among several organizations involved in Project PrEPPY, a multiagency collaboration with experts from government, academia, and multilateral and nongovernmental organizations.

Special Reports

In September 2017, TREAT Asia created the first in a series of infographics titled *Why Has Asia Fallen Behind on HIV/AIDS?* to illustrate the stagnation in HIV program coverage in the



Volunteers at the Love Yourself organization, which is co-leading "Project PrEPPY" in the Philippines



The first in a series of three infographics showing the need for greater progress on HIV/AIDS in the Asia-Pacific region

and Improving Population Health. The report documents the slow uptake of HPV vaccination in the region and gives recommendations for increasing use of the vaccine. Also with the Public Policy Office, in March 2017, TREAT Asia published the fact sheet *PrEP Acceptability Among Female Sex Workers in Thailand: Key Research Findings*, based on a study jointly conducted by the Institute for Population and Social Research at Mahidol University in Bangkok, Johns Hopkins Bloomberg School of Public Health in Baltimore, and the community-based organization Service Workers in Group (SWING) Foundation.

Public Policy

Informed by thorough research and analysis, amfAR is a highly respected advocate of rational and compassionate AIDS-related public policy. Through its Public Policy Office in Washington, DC, amfAR educates policymakers, the media, and the public about evidence-based policies to address HIV/AIDS in the U.S. and around the world.

Ending the Domestic HIV Epidemic

In October 2016, amfAR published a report that recommends several measures health plans and healthcare purchasers can take to help end the domestic HIV epidemic. *Curbing the HIV Epidemic by Supporting Effective Engagement in HIV Care: Recommendations for Health Plans and Health Care Purchasers* outlines actionable steps to improve health outcomes, reduce unnecessary spending, and contribute to the development of more integrated systems of care for people living with HIV.

Capitol Hill Briefing

In June 2017, government officials, scientists, and public health leaders convened at an amfAR Capitol Hill conference titled,


Asia-Pacific, and to remind governments, civil society, and donors that much more needs to be done to bring HIV/AIDS under control in the region.

In conjunction with amfAR's Public Policy Office, in November 2016, TREAT Asia produced a report titled *Cervical Cancer, Human Papillomavirus (HPV), and HPV Vaccines in Southeast Asia: Key Considerations for Expanding Vaccine Coverage*

“Making AIDS History: A Roadmap for Ending the Epidemic.” The conference highlighted the latest advances in HIV prevention, treatment, and research and addressed the challenges that remain in eradicating the virus. Speakers and panelists discussed the national security implications of epidemics, the economic and health impact of aging with HIV, and the opioid crisis and its relationship to HIV and other infectious diseases.

HIV and the Opioid Epidemic

Also in June 2017, amfAR launched a comprehensive online database to help communities, policymakers, and advocates effectively respond to the opioid epidemic. The Opioid & Health Indicators Database (opioid.amfar.org) provides local and national statistics on HIV and hepatitis C infections, opioid use, overdose death rates, and the availability of services such as drug treatment and syringe services programs. The Foundation also published an issue brief outlining the case for supervised consumption services (SCS), which provide a hygienic space for people to use illicit drugs under the supervision of trained staff.



amfAR's Opioid & Health Indicators database is a comprehensive and invaluable resource for communities, lawmakers, and advocates.

Global Health

In January 2017, amfAR published a report arguing that a cure alone will not end the HIV epidemic, and that only with a coordinated and enduring commitment can any disease be controlled. Using tuberculosis and malaria as examples, *How Cures Can Fail* shows that global efforts to eradicate widespread diseases can fail even when effective cures are available.

In June 2017, amfAR published *Derailing Progress: The Human Impact of the U.S. FY2018 Global Health Budget*, an infographic showing the impact of \$800 million in proposed cuts to the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) and USAID in fiscal year 2018, a 17% decrease. Such a substantial reduction in funding could cause more than a million HIV treatment disruptions for both children and adults, new HIV infections, and 146,000 preventable AIDS-related deaths.

amfAR also published an issue brief outlining the potential impact of President Trump's action reinstating and expanding the Mexico City Policy. The policy has historically prohibited U.S. family planning funding for non-U.S. nongovernmental organizations performing or promoting abortion.

In the News

In March 2017, amfAR Senior Policy and Medical Advisor Dr. Susan Blumenthal penned an op-ed for National Women and Girls HIV/AIDS Awareness Day warning of the implications of repealing the Affordable Care Act and limiting access to healthcare. The op-ed was published online on *The Advocate* and *HuffPost*.

In June 2017, Greg Millett, amfAR's vice president and director of public policy, was widely quoted in a *New York Times Magazine* article titled "America's Hidden H.I.V. Epidemic: Why do America's black gay and bisexual men have a higher H.I.V. rate than any country in the world?" The piece focused on Jackson, MS, which has the nation's highest rate of gay and bisexual men (40%) living with HIV.

Also in June, amfAR policy associate Alana Sharp and Dr. Rahul Gupta, public health commissioner and state health officer for West Virginia, published an opinion piece in *The Hill* on the impact of proposed cuts to the CDC and Medicaid affecting efforts to combat the opioid epidemic. West Virginia has the highest drug-related death rate in the country.

The GMT Initiative

Since 2007, amfAR has been serving the HIV-related needs of gay men, other men who have sex with men (MSM), and transgender individuals (collectively, GMT) throughout the developing world through its GMT Initiative. Through small, targeted grants to grassroots groups, amfAR has expanded access to HIV education and prevention services; supported advocacy aimed at increasing funding for prevention and treatment services; and worked to end the stigma, discrimination, and violence that threaten the lives of GMT and fuel the spread of HIV/AIDS.

Implementation Science Awards

In FY2017, amfAR's grant making through the GMT Initiative evolved to support larger implementation science projects aimed at identifying barriers to HIV testing, treatment, and care and studying the impact of innovative HIV service delivery models for GMT in low- and middle-income countries. amfAR has awarded \$2.6 million over three years to support three such studies.

- ▶ Dr. Chris Beyrer of Johns Hopkins University is leading a team of researchers and community-based services (in collaboration with the International HIV/AIDS Alliance Myanmar) in evaluating the effectiveness of promising interventions for GMT in Myanmar, where increased HIV testing and treatment opportunities are becoming available. The researchers are assessing the effectiveness of HIV self-testing done in the privacy of one's home, point-of-care CD4 testing, and the use of "peer navigators" familiar with the local health system to help newly diagnosed individuals gain access to HIV treatment and care.
- ▶ In Lima, Peru, Dr. Javier Lama of Asociación Civil Impacta Salud y Educación and his team are aiming to improve the continuum of care among transgender women by using an innovative model that integrates HIV prevention and treatment services with transgender-affirming medical care.



University of Pittsburgh/amfAR HIV Scholars (left to right): Daniel Dutra de Barros, Dr. Antonio Spagnolo, Kabelo Maleke, Adi Nugroho

- ▶ And in Bangkok, Thailand, Dr. Nittaya Phanuphak and her team at the Thai Red Cross AIDS Research Centre are working to show how innovative technologies such as GMT-targeted websites using online counseling and support can be utilized to increase rates of HIV testing and referrals to prevention and treatment programs.

amfAR HIV Scholars Program

In December 2016, amfAR and the University of Pittsburgh produced a supplement to the journal *AIDS and Behavior* devoted to the HIV Scholars Program at the university's Center for LGBT Health Research. The program's mission is to support the creation of public health responses to dramatic HIV health disparities among GMT in low- and middle-income countries. The amfAR-funded program has supported research training for 16 young investigators from a wide range of countries, including Pakistan, China, Lebanon, and Belize, among others.

In FY2017, amfAR supported four young HIV Scholars from Paraguay, Brazil, South Africa, and Indonesia undergoing five months of graduate-level public health study at the Center for LGBT Health Research at the University of Pittsburgh Graduate School of Public Health. The current HIV Scholars are Dr. Antonio Spagnolo of the National University of Asunción in Paraguay; Daniel Dutra de Barros of Santa Casa de São Paulo School of Medical Sciences in Brazil; Kabelo Maleke of Project Boithato at the Anova Health Institute in rural South Africa; and Adi Nugroho of the GWL-INA Network in Jakarta, Indonesia.

Public Information

amfAR disseminates information on important HIV-related research, treatment, prevention, and policy issues for diverse audiences, increasing awareness and knowledge of the pandemic. amfAR publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, scientists, and policymakers in communicating the need for continued research on HIV/AIDS.

Educational Materials

amfAR produces a range of periodicals in both print and electronic formats, including its newsletter *Innovations*, published twice a year and distributed to more than 40,000 people; the *TREAT Asia Report*, an email newsletter distributed six times a year to more than 4,000 readers in the international health community; and a monthly e-mail newsletter distributed to nearly 70,000 people. The Foundation's websites—www.amfar.org and www.curecountdown.org—feature news, interviews, and original articles covering HIV research, policy, the global epidemic, and amfAR programs and activities. The websites attract a combined average of 45,000 visitors per month. amfAR also creates and distributes reports, press releases, and updates on major HIV/AIDS issues and conducts public service advertising campaigns that have been instrumental in educating policymakers, healthcare professionals, people living with HIV/AIDS, and the public.

Epic Voices

In June 2017, amfAR launched Epic Voices, an online video series that aims to reenergize the response to HIV among millennial and LGBTQ communities. The goals of the campaign are to renew awareness of the persistent threat of HIV, underscore the urgent need to support HIV research, and support amfAR's leadership in the search for a cure. For the series, amfAR has spoken with HIV activists across the country, asking them to share their unique journeys, their insights on living with HIV, and the bold steps they have taken in the fight against the epidemic.

Social Media

amfAR continues to expand its presence in the social media arena, reaching large numbers of people, including a younger demographic that is often less educated about HIV and the AIDS epidemic. The Foundation regularly adds content to its Facebook page, live tweets

from events, and posts images on Instagram from fundraising and program events. amfAR has 74,000 likes on Facebook, 43,000 Twitter followers, and more than 130,000 Instagram followers.

Media Outreach

In FY2017, amfAR continued to work closely with the media to raise the profile of HIV/AIDS, both domestically and internationally, and to help ensure the accuracy of HIV-related press coverage. Articles and reports involving amfAR—many of which included interviews with staff—were carried in numerous media outlets, including *The New York Times*, *The Washington Post*, the *Chicago Tribune*, *The Hill*, *Politico*, NBC News, CBS News, CNBC, *U.S. News & World Report*, Reuters, *Ebony*, and *HuffPost*.


Celebrity Support

amfAR's public awareness efforts are greatly enhanced by the committed support of public figures who lend their voices and donate their time, talents, and resources to help sustain the Foundation's mission. Support of amfAR by prominent public figures began with the late Dame Elizabeth Taylor, amfAR's Founding International Chairman, and many have followed in her footsteps.

Other celebrity supporters include amfAR Ambassadors Milla Jovovich, Michelle Yeoh, Cheyenne Jackson, and Liza Minnelli, as well as Charlize Theron, Adrien Brody, Jessica Chastain, Matt Bomer, Dita Von Teese, Gwyneth Paltrow, Diana Ross, Chiara Ferragni, Diane Kruger, Iman, Katie Holmes, Uma Thurman, Kate Moss, Zac Posen, Zoe Saldana, Tobey Maguire, Dame Helen Mirren, Lea Michele, Michelle Rodriguez, Will Smith, Nicole Kidman, Naomi Campbell, Heidi Klum, Jon Hamm, Eva Longoria, Leonardo DiCaprio, Robert De Niro, Nicki Minaj, Andrea Bocelli, Dean and Dan Caten, Chris Tucker, Jennifer Garner, Scarlett Johansson, Donatella Versace, Victoria Justice, and Carine Roitfeld.

EPIC VOICES

amfAR's Epic Voices debuted in June 2017, with the personal—and often inspirational—stories of five people living with HIV who discuss how the virus has affected their lives and what a cure would mean for them. The online video series aims to inspire millennials and LGBT communities to support HIV/AIDS research and amfAR's mission to find a cure.



amfAR
COUNTDOWN
TO A CURE FOR AIDS

2017 RESEARCH GRANTS, FELLOWSHIPS AND AWARDS

All projects listed below were awarded funding during the period October 1, 2016, through September 30, 2017.

amfAR RESEARCH CONSORTIUM ON HIV ERADICATION (ARCHE)

Allogeneic stem cell transplant in HIV-1-Infected Individuals (second renewal)

Annemarie Wensing, MD, PhD
University Medical Center Utrecht
Utrecht, The Netherlands
Javier Martinez-Picado, PhD
AIDS Research Institute, irsiCaixa
Barcelona, Spain
\$997,518

ARCHE: GENE THERAPY TO CURE HIV

Vector-mediated *in vivo* targeting of HIV reservoir cells for provirus elimination

Hildegard Büning, Dr. rer. nat. (PhD)
Hannover Medical School
Hannover, Germany
\$386,578

Subcutaneous administration of DARPIn-modified adeno-associated virus vectors for selective targeting of CD4+ T cells

Keith Jerome, MD, PhD
University of Washington
Seattle, WA
\$399,955

Engineering blood cells to produce broadly neutralizing anti-HIV antibodies

Hans-Peter Kiem, MD, FACP
Fred Hutchinson Cancer Research Center
Seattle, WA USA
\$200,000

Optimized efficacy and persistence of engineered HIV-specific cellular immunity

Scott Kitchen, PhD
University of California, Los Angeles
Los Angeles, CA
\$400,000

LentiStim: mass production of lentiviral vectors for *in vivo* gene delivery

Yasuhiro Takeuchi, PhD
University College London
London, United Kingdom
\$360,034

Targeting of nucleic acid therapeutics to cure HIV

Drew Weissman, MD, PhD
Trustees of the University of Pennsylvania
Philadelphia, PA
\$400,000

CAR T cells dually encoding alpha-chain-anchored and soluble broadly neutralizing antibodies to HIV

Richard T. Wyatt, PhD
International AIDS Vaccine Initiative
New York, NY
\$199,362

INVESTMENT GRANTS: BRINGING BIOENGINEERS TO CURE HIV – PHASE I

Single-cell transcriptomic analysis of HIV reservoirs before and after systemic interleukin-2 (IL-2) therapy

Eli Boritz, MD, PhD
Foundation for the National Institutes of Health
Bethesda, MD
\$200,000

Single cell levitation to identify, isolate and characterize HIV reservoirs

Timothy Henrich, MD
University of California, San Francisco
San Francisco, CA
\$200,000

Targeted nanocarriers to accelerate depletion of the HIV reservoir

Keith Jerome, MD, PhD
University of Washington
Seattle, WA
\$200,000

Targeted inactivation of integrated HIV through host cell DNA repair pathways

Priti Kumar, PhD
Yale University
New Haven, CT
\$200,000

Bifunctional nucleases programmed by HIV-1 mRNA for reservoir eradication

Jeremy Luban, MD
University of Massachusetts Medical School
Worcester, MA
\$200,000

Deciphering latency-associated sugar-code to detect and eliminate latent reservoir

Hui Zhang, PhD
Johns Hopkins University
Baltimore, MD
\$199,444

INNOVATION GRANTS: EXPLORING THE POTENTIAL FOR HIV ERADICATION

Ixazomib to reduce HIV reservoir size

Andrew Badley, MD
Mayo Clinic College of Medicine
Rochester, MN
\$200,000

Creation of CCR5 knockout Mauritian cynomolgus macaques for stem cell transplants

Benjamin Burwitz, PhD
Oregon Health and Science University
Portland, OR
\$199,948

Disabling HIV provirus by promoting chromatinization

Andrew Henderson, PhD
Boston University School of Medicine
Boston, MA
\$200,000

HLA-E-specific TCR-like antibodies for the universal targeting of persistent HIV reservoirs

Brad Jones, PhD
The George Washington University
Washington, DC
\$199,998

Permanent silencing of HIV-1 expression through the polycomb repressor complex 2 epigenetic pathway

Fabio Romero, PhD
University of Maryland at Baltimore
Baltimore, MD
\$199,999

Anti-proliferative therapy for eradication of the HIV reservoir

Joshua Schiffer, MD, MSc
Fred Hutchinson Cancer Research Center
Seattle, WA
\$200,000

MATHILDE KRIM FELLOWSHIPS IN BASIC BIOMEDICAL RESEARCH

Impact of pre-adaptation on viral evolution and virus control in the newly infected individual

Daniela Monaco, PhD
Emory University
Atlanta, GA
\$150,000

Exploiting dynamic conformational states of HIV-1 Env as targets for novel inhibitors

Gabriel Ozorowski, PhD
The Scripps Research Institute
La Jolla, CA
\$150,000

Harnessing NK cell responses to eliminate HIV-1-infected cells

Jonathan Richard, PhD
Université de Montréal, Centre de Recherche du CHUM
Montreal, Canada
\$150,000

PHASE II MATHILDE KRIM FELLOWSHIP GRANT

Structural analyses of antibody-virus complexes to guide immunogen design

Daniela Fera, PhD
Swarthmore College
Swarthmore, PA
\$80,000

MEETINGS AND CONFERENCES

Advanced Course on HIV Pathogenesis, XII Edition

Esper Kallás, MD, PhD
Fundação Faculdade de Medicina
São Paulo, Brazil
\$15,000

2017 TREAT ASIA GRANTS AND AWARDS

All projects listed below were awarded funding during the period October 1, 2016, through September 30, 2017.

¹Supported by National Institutes of Health cooperative agreement number U01AI069907 with funds from the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Cancer Institute, the National Institute of Mental Health, and the National Institute on Drug Abuse

²Supported by National Institutes of Health grant number R01HD073972 funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development

³Supported by National Institutes of Health grant number R21HD089859 funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development

⁴Supported with funds provided by ViiV Healthcare

⁵Supported with funds provided by LIFE+

⁶Supported with fund provided by the Open Society Foundations

AUSTRALIA

University of New South Wales

Sydney
Matthew G. Law, PhD
IeDEA Asia-Pacific Research Collaboration: Cancer Studies
\$77,277¹

IeDEA Asia-Pacific Research Collaboration: TREAT Asia HIV Observational Database & Australia HIV Observational Database
\$299,701¹

IeDEA Asia-Pacific Research Collaboration: TREAT Asia Pediatric HIV Observational Database
\$207,583¹

AUSTRALIA HIV OBSERVATIONAL DATABASE (AHOD) SITES

O'Brien Street Practice

Adelaide
William Donohue, MBBS
\$1,800

Sexual Health and HIV Service In Metro North Brisbane

Diane Rowling, MBBS, FAFPHM, RACP, FACHSHM
\$3,825

Cairns Sexual Health Service

Cairns
Darren Russell, MD
\$7,500¹

RPA Sexual Health Clinic

Camperdown
David Templeton, PhD
\$5,550

Melbourne Sexual Health Centre

Carlton
Tim Read, MBBS, DipVen, FRACGP, FACHSHM, EpiDip
\$6,225¹

Monash Health - Clayton

Clayton
Ian Woolley, MBBS, FRACP
\$7,500¹

D.A. Ellis Pty Ltd

Coffs Harbour
David Ellis, MBBS
\$675

East Sydney Doctors

Darlinghurst
David Baker, MB, ChB, Dip Med (Sexual Health), DCH
\$6,675¹

St. Vincent's Hospital Sydney Limited ABN 77 054 038 872

Darlinghurst
David A. Cooper, MD
\$7,500¹

Taylor Square Private Clinic

Darlinghurst
Robert Finlayson, MBBS (Syd), Di
\$6,975¹

Northern Territory Dept of Health & Community Services, Sexual Health & Blood Borne Virus Program

Darwin
Manoji Gunathilake, MBBS, MD, FACHSHM
\$1,800

Gladstone Road Medical Centre

Highgate Hill
David Orth, MBBS, DIP Ven
\$6,525¹

Nepean Blue Mountains Local Health District, Blue Mountains Sexual Health and HIV Clinic

Katoomba
Eva Jackson, MBBS, FACHSHM
\$2,025

Nepean Blue Mountains Local Health District, Nepean Sexual Health Clinic

Kingswood
Eva Jackson, MBBS, FACHSHM
\$2,100

Sexual Health and AIDS Services (SHAIDS)

Lismore
David Smith, MBBS, DipVen, FACHSHM, GrapDip, BA
\$7,500¹

Victorian HIV Service, Infectious Diseases Department, The Alfred Hospital

Melbourne
Jennifer Hoy, MBBS
\$7,500¹

Sunshine Coast Hospital and Health Service

Nambour West
David Sowden, MBBS
\$7,500¹

Northside Clinic (Vic) Pty Ltd

North Fitzroy
Richard Moore, MBBS
\$7,500¹

Royal Perth Hospital

Perth
David Nolan, MBBS, FRACP, PhD
\$6,825¹

Prahran Market Clinic Pty Ltd

Prahran
Norman Roth, MBBS, FACHSHM
\$6,825¹

Holdsworth House Medical Practice

Sydney
Mark Bloch, MD
\$7,500¹

Sydney Sexual Health Centre, Sydney Hospital

Sydney
Rick Varma, MBBS, MRCP
\$6,600¹

Clinic 468, HNE Sexual Health, Hunter New England Local Health District

Tamworth
Nathan Ryder, MD
\$1,575

Illawarra Shoalhaven Local Health District

Warrawong
Katherine Brown, MD
\$1,800

CAMBODIA

National Center for HIV/AIDS, Dermatology & STDS / Cambodia National Institute of Public Health

Phnom Penh
Ly Penh Sun, MD, MSc
TAHOD Low Intensity Transfer (TAHOD LITE)
\$8,000¹

TREAT Asia HIV Observational Database (TAHOD)
\$20,000¹

TREAT Asia Pediatric HIV Observational Database (TAPHOD)
\$25,000

CHINA

Beijing Ditan Hospital

Beijing
Fujie Zhang, MD, MSPH, PhD
TREAT Asia HIV Observational Database (TAHOD)
\$18,500¹

Queen Elizabeth Hospital

Hong Kong
Man Po Lee, MBBS
TAHOD Low Intensity Transfer (TAHOD LITE)
\$6,500¹

Man Po Lee, MBBS
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$23,000¹

INDIA

Chennai Antiviral Research and Treatment Clinical Research Site (CART CRS), YRG CARE Medical Centre, VHS

Chennai
Naglingeswaran Kumarasamy, MD, MBBS, PhD
TAHOD Low Intensity Transfer (TAHOD LITE)
\$5,000

TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$21,800¹

TREAT Asia Pediatric HIV Observational Database (TApHOD) Site
\$7,500

B.J. Medical College

Pune
Aarti Kinikar, MD, DCH, DNB, MRCP
TREAT Asia Pediatric HIV Observational Database (TApHOD) Site
\$20,000¹

Shahshikala Sangle
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$22,550¹

B.J. Medical College—Johns Hopkins University

Pune
Vidya Mave, MD, MPH
Epidemiology of HIV/AIDS and associated comorbidities in a public antiretroviral treatment (ART) clinic in Pune, India
\$212,551¹

Institute of Infectious Diseases

Pune
Sanjay Pujari, MD, AAHIVS, MBBS
TAHOD Low Intensity Transfer (TAHOD LITE)
\$7,992
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$22,400¹

INDONESIA

Sanglah Hospital, Udayana University School of Medicine

Denpasar, Bali
Tuti Parwati Merati, MD, PhD
TAHOD Low Intensity Transfer (TAHOD LITE)
\$6,500¹

TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$22,550¹

Ketut Dewi Kumara Wati, MD
TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$7,500

Cipto Mangunkusumo General Hospital

Jakarta
Nia Kurniati, MD
TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$7,500¹

Evy Yunihastuti, MD, PhD
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$22,800¹

JAPAN

National Center for Global Health and Medicine

Shinjuku
Junko Tanuma, MD, PhD
TREAT Asia HIV Observational Database (TAHOD)
\$16,000¹

MALAYSIA

Penang Hospital

Georgetown
Revathy Nallusamy, MBBS
TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$2,500

Hospital Raja Perempuan Zainab II

Kota Bharu
Nik Khairulddin Nik Yusoff, MD
TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$7,500

Hospital Likas

Kota Kinabalu
Fong Siew Moy, MBBS
TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$7,500

Pediatric Institute, Hospital Kuala Lumpur

Kuala Lumpur
Thahira Mohamed, MBBS
TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$7,500

University of Malaya

Kuala Lumpur
Adeeba Kamarulzaman, MBBS, FRACP, FAMM, FASC
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$22,700¹

Sungai Buloh Hospital

Sungai Buloh
Yasmin Mohamed Gani, MD
Study of Transitioning Asian Youth (STAY)
\$6,986⁴

Benedict Lim Heng Sim, MBBS, MRCP
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$16,000¹

NEPAL

Union C

Kathmandu
Himal Gauchan
Hepatitis C capacity development for community groups
\$8,399⁶

SINGAPORE

Tan Tock Seng Hospital

Singapore
Oon Tek Ng, MBBS, MRCP, MMed, MPH
TAHOD Low Intensity Transfer (TAHOD LITE)
\$5,000¹

TREAT Asia HIV Observational Database (TAHOD)
\$18,000¹

SOUTH AFRICA

University of Cape Town

Mowbray
Mary-Ann Davies, MBChB, MMed., FCPHM
Global fRAMework for Data Collection Used for Adolescent HIV Transition Evaluation (GRADUATE)
\$102,105³ (Year 1) \$91,477³ (Year 2)

SOUTH KOREA

Yonsei University College of Medicine

Seoul
Jun Yong Choi, MD, PhD
TAHOD Low Intensity Transfer (TAHOD LITE)
\$5,000¹

TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$18,200¹

TAIWAN

Taipei Veterans General Hospital

Taipei City
Wing-Wai Wong, MD
TAHOD Low Intensity Transfer (TAHOD LITE)
\$5,000¹

TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$26,000¹

THAILAND

Chulalongkorn University

Bangkok
Thanyawee Puthanakit, MD
Neurodevelopmental and neurobehavioral outcomes in HIV-exposed children
\$10,174¹ (Year 1) \$13,883¹ (Year 2)

TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$15,000¹

HIV-NAT / Thai Red Cross AIDS Research Centre

Bangkok
Anchalee Avihingsanon, MD, PhD
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$23,200¹

Sivaporn Gatechompol
Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia
\$15,082²

Watsamon Jantarabenjakul, MD
Treatment switch from efavirenz to rilpivirine in virologically-suppressed HIV-infected Thai adolescents
\$2,355

Stephen Kerr, PhD
Study of Transitioning Asian Youth (STAY) Statistical Analysis Center
\$10,046¹

Understanding adherence, stigma, and behavioral risk factors of adolescents in TApHOD using ACASI (data analysis center)
\$4,000¹

Nittaya Phanuphak, MD, PhD
Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia (central lab & data management)
\$110,962²

Amphetamine-type stimulant use, HIV incidence, and ART adherence among Thai MSM and transgender women
\$32,670¹ (Year 1) \$75,601¹ (Year 2)

Anal HPV and risk for anal high-grade squamous intraepithelial lesion among Thai MSM with acute HIV infection
\$30,179¹ (Year 1) \$77,359¹ (Year 2)

Mahidol University by Faculty of Medicine Siriraj Hospital
Bangkok
Kulkanya Chokeyphaibulkit, MD
Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia
\$11,658²

Study of Transitioning Asian Youth (STAY)
\$12,454¹

TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$15,000¹

Treatment switch from efavirenz to rilpivirine in virologically-suppressed HIV-infected Thai adolescents
\$7,961

Queen Sirikit National Institute of Child Health
Bangkok
Piyarat Suntarattiwong, MD
Treatment switch from efavirenz to rilpivirine in virologically-suppressed HIV-infected Thai adolescents
\$6,260

Ramathibodi Hospital, Mahidol University
Bangkok
Sasisopin Kiertiburanakul, MD, MHS
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$23,000¹

Chiang Mai University - Research Institute for Health Sciences
Chiang Mai
Romane Chaiwarith, MD, MHS
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$23,900¹

Tavitiya Sudjaritruk, MD, ScM
TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$15,000¹

Chiangrai Prachanukroh Hospital
Chiang Rai
Raviwan Hansudewechakul, MD
Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia
\$11,102²

Study of Transitioning Asian Youth (STAY)
\$10,172⁴

TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$15,000¹

Suwimon Khusuwan
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$22,500¹

Srinagarind Hospital, Khon Kaen University
Khon Kaen
Pagakrong Lumbiganon, MD
Study of Transitioning Asian Youth (STAY)
\$11,599⁴

TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$7,500

Purple Haze Company Limited
Muang
Tarandeep Anand
The impact of online interventions on the HIV prevention/treatment cascade among MSM and TG Individuals
\$30,028¹ (Year 2) \$30,000¹ (Year 3)

USA

Massachusetts General Hospital
Boston, MA
Andrea Ciaranello, MD, MPH
Estimating the magnitude of the pediatric and adolescent HIV epidemic in Thailand
\$45,000⁵

VIETNAM

Bach Mai Hospital
Hanoi
Do Duy Cuong, MD, PhD
TAHOD Low Intensity Transfer (TAHOD LITE)
\$6,500¹

TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$22,670¹

Nguyen Van Lam, MD, MSc
Study of Transitioning Asian Youth (STAY)
\$8,803⁴

TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$20,000¹

Nguyen Van Kinh, MD, PhD
TAHOD Low Intensity Transfer (TAHOD LITE)
\$6,500¹

TREAT Asia HIV Observational Database (TAHOD) including NCD Data
\$22,560¹

Children's Hospital 1
Ho Chi Minh City
Tran Ngoc Hanh Dan, MD, MSc
Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia
\$4,802²

Truong Huu Khanh, MD
TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$25,000¹

Do Chau Viet, MD
TREAT Asia Pediatric HIV Observational Database (TApHOD)
\$20,000

Hung Vuong Hospital
Ho Chi Minh City
Dang Le Dung Hanh, MD (OB&GYN), MA
Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia
\$4,649²

2017 GMT INITIATIVE GRANTS AND AWARDS

All projects listed below were awarded amfAR funding during the period October 1, 2016, through September 30, 2017.

amfAR HIV SCHOLARS AWARDS

Structural intervention models for HIV prevention among young gay men and transgender individuals in central São Paulo
Daniel Barros
Santa Casa School of Medical Sciences
São Paulo, Brazil
\$25,000

Pilot study on HIV among men who have sex with men in Belize (supplement)
Erika Castellanos
Collaborative Network of Persons Living with HIV (C-NET+)
Belize City, Belize
\$1,800

Project Power-Up – Developing a peer support group for HIV-positive GMT in Mpumalanga, South Africa
Kabelo Maleke
Anova Health Institute
Cape Town, South Africa
\$25,000; Supplement: \$862

Developing 'GAP,' a smartphone application for daily self-monitoring and self-management for HIV-positive MSM
Adi Nugroho
GWL-INA
Jakarta, Indonesia
\$25,000

HIV care access and retention in Paraguay: A comparative analysis of the country's first LGBT clinic
Antonio Spagnolo, MD
Fundación Vencer
Asunción, Paraguay
\$23,000

2017 PUBLIC POLICY AWARDS

The projects listed below were awarded amfAR funding during the period October 1, 2016, through September 30, 2017.

*Funded with support from the Ford Foundation

Building power in prevention advocacy among transgender African advocates

Emily Bass
AIDS Vaccine Advocacy Coalition (AVAC)
New York, NY
\$49,999

Scrutinizing PEPFAR Investments in South Africa

Matthew Kavanagh, PhD
Georgetown University
Washington, DC
\$47,928

Qualitative evaluation of retention at the Moore Clinic

Catherine Maulsby, PhD
Johns Hopkins University
Baltimore, MD
\$99,942*

2017 COMMUNITY OUTREACH AWARDS

The projects listed below were awarded amfAR funding during the period October 1, 2016, through September 30, 2017.

Dr. Mathilde Krim/amfAR Professorship of Global Health Fund

Columbia University
New York, NY
\$500,000

Andrea Bocelli Foundation—Health Care Needs of People Living with HIV in Haiti

Charities Aid Foundation of America (CAF America)
Alexandria, VA
\$224,260

Charlize Theron Africa Outreach Project

New Venture Fund
Washington, DC
\$500,000



Financial Highlights




For the year ended September 30, 2017


Public Support and Revenue		
Public support	\$	6,281,507
Special events		18,185,017
Planned giving		3,157,413
Government funding		11,578,195
Investment income and other revenue		2,355,134
Total public support and revenue	\$	41,557,266
<hr/>		
Expenses		
Research	\$	22,716,644
TREAT Asia		4,581,509
GMT Initiative		1,272,304
Public Policy		2,202,676
Public Information		4,230,300
Total program services	\$	35,003,433
<hr/>		
Fundraising		5,779,044
Management and general		2,683,723
Total supporting services	\$	8,462,767
<hr/>		
Total expenses	\$	43,466,200
<hr/>		
Change in net assets		(1,908,934)
Net assets, beginning of year		61,639,180
Net assets, end of year	\$	59,730,246

Statement of Financial Position






Assets		
Cash and investments	\$	63,694,070
Pledges and receivables, net		8,619,990
Prepaid expenses and other assets		4,833,160
Furniture, equipment, and leasehold improvements, net		3,074,500
Total Assets	\$	80,221,720
<hr/>		
Liabilities		
Accounts payable and accrued expenses	\$	3,028,826
Grants and fellowships payable, net		3,445,162
Deferred support and refundable advances		11,985,013
Other long-term liabilities		2,032,473
Total liabilities	\$	20,491,474
<hr/>		
Total net assets		59,730,246
<hr/>		
Total liabilities and net assets	\$	80,221,720


Expenses

	Fundraising	\$	5,779,044
	Management and general		2,683,723
	Program		35,003,433
Total		\$	43,466,200



Program Expenses

	Research	\$	22,716,644
	TREAT Asia		4,581,509
	GMT Initiative		1,272,304
	Public Policy		2,202,676
	Public Information		4,230,300
Total		\$	35,003,433



BOARD OF TRUSTEES

Fiscal year 2017

Chairman of the Board

Kenneth Cole

Chairman
Kenneth Cole Productions
New York, NY

Founding Chairman

Mathilde Krim, Ph.D.

Adjunct Professor
Mailman School of Public Health
Columbia University
New York, NY

Vice Chairman

Patricia J. Matson

Senior Vice President, Communications (ret.)
ABC, Inc.
New York, NY

Vice Chairman and Treasurer

John C. Simons

Managing Partner
Corporate Fuel Partners, LLC
New York, NY

Secretary

Mervyn F. Silverman, M.D., M.P.H.

President
Mervyn F. Silverman Associates
Crockett, CA

TRUSTEES

Arlen H. Andelson

Senior Partner (ret.)
Andelson & Andelson
Los Angeles, CA

Harry Belafonte

President
Belafonte Enterprises, Inc.
New York, NY

David Bohnett

Chairman
David Bohnett Foundation
Beverly Hills, CA

Zev Braun

President and CEO
Braun Entertainment Group, Inc.
Beverly Hills, CA

Jonathan S. Canno

New York, NY

Donald A. Capoccia

Managing Principal
BFC Partners
Brooklyn, NY

R. Martin Chavez, Ph.D.

Chief Information Officer
The Goldman Sachs Group, Inc.
New York, NY

Jane B. Eisner

President
The Eisner Foundation
Bel Air, CA

Jay Ellis

Jay Ellis Foundation
Studio City, CA

Aileen Getty

The Aileen Getty Foundation
Del Mar, CA

T. Ryan Greenawalt

Managing Director
Ramirez & Co.
President
Harrison Street Productions
New York, NY

Regan Hofmann

Policy Officer
U.S. Liaison Office
UNAIDS
Washington, D.C.

Michael J. Klingensmith

Publisher and CEO
Star Tribune
Minneapolis, MN

Kevin McClatchy

Chairman of the Board
The McClatchy Company
Ligonier, PA

Michele V. McNeill, Pharm.D.

Chairman
McNeill Family Foundation
Sarasota, FL

Edward L. Milstein

Co-Chairman, Milford Management
Co-Chairman, Emigrant Savings Bank
Partner, Milstein Properties
New York, NY

Peter Piot, M.D., Ph.D.

Director
London School of Hygiene & Tropical Medicine
London, UK

Cindy D. Rachofsky

Philanthropist
Dallas, TX

Vincent A. Roberti

Chairman, Roberti Global, LLC
Managing Director, Roberti Associates Global, LLC
Washington, D.C.

Bill Roedy

London, UK

Raymond F. Schinazi, Ph.D., D.Sc.

Frances Winship Walters Professor of Pediatrics
Director, Laboratory of Biochemical Pharmacology
Emory University
Decatur, GA

Alan D. Schwartz

Executive Chairman
Guggenheim Partners, LLC
New York, NY

Diana L. Taylor

Vice Chair
Solera Capital, LLC
New York, NY

TRUSTEE EMERITUS

Arthur J. Ammann, M.D.

President, Global Strategies for HIV Prevention
Clinical Professor of Pediatrics
University of California, San Francisco
San Francisco, CA

IN MEMORIAM

Dame Elizabeth Taylor

Founding International Chairman

Sheldon W. Andelson, Esq.

Arnold W. Klein, M.D.
Mrs. Albert D. Lasker
Jonathan M. Mann, M.D., M.P.H.
Maxine Mesinger
Pauline Phillips
Natasha Richardson
Allan Rosenfield, M.D.
Peter Scott, Esq.
Tom Stoddard
Joel D. Weisman, D.O.

SPECIAL APPOINTMENTS

Global Campaign Chair
Sharon Stone

Global Fundraising Chairman
Milutin Gatsby

amfAR AMBASSADORS

Cheyenne Jackson

Janet Jackson
Milla Jovovich
Liza Minnelli
Michelle Yeoh

COMMITTEES OF THE BOARD OF TRUSTEES

Executive

Kenneth Cole, Chair
Michael J. Klingensmith
Mathilde Krim, Ph.D.
Patricia J. Matson
Vincent A. Roberti
Mervyn F. Silverman, M.D., M.P.H.
John C. Simons

Audit

John Simons, Chair
R. Martin Chavez, Ph.D.
T. Ryan Greenawalt

Board Development

Donald A. Capoccia, Co-Chair
Patricia J. Matson, Co-Chair
Arlen Andelson
T. Ryan Greenawalt
Bill Roedy
Mervyn F. Silverman, M.D., M.P.H.

Communications/Social Media/Marketing

Regan Hofmann, Chair
Kenneth Cole
T. Ryan Greenawalt
Patricia J. Matson
Kevin McClatchy
Vincent A. Roberti
Bill Roedy

Compensation and Organizational Development

John C. Simons, Chair
Michael J. Klingensmith
Kevin McClatchy

Finance & Budget

Michael J. Klingensmith, Chair
Vincent A. Roberti
John C. Simons

Fund Development

Vincent A. Roberti, Chair
Arlen Andelson
Jonathan S. Canno
Donald A. Capoccia
T. Ryan Greenawalt
Cindy D. Rachofsky
Raymond F. Schinazi, Ph.D., D.Sc.

Investment

Michael J. Klingensmith, Chair
R. Martin Chavez, Ph.D.
T. Ryan Greenawalt
Edward L. Milstein
Vincent A. Roberti
John C. Simons

SCIENTIFIC ADVISORY COMMITTEE

*Adjunct Member

Daniel C. Douek, M.D., Ph.D. (Chair)
Chief, Human Immunology Section
Vaccine Research Center
National Institute of Allergy and Infectious Diseases
National Institutes of Health

Margaret Ackerman, Ph.D.*
Associate Professor of Engineering
Thayer School of Engineering
Dartmouth College

Richard Ambinder, M.D., Ph.D.*
Director, Division of Hematologic Malignancies
Professor of Oncology
School of Medicine
Johns Hopkins University

Angelina Angelova, Ph.D.*
Research Associate
Physico-Chimie des Systèmes Polyphasés
Université Paris-Sud

Patrick Arbuthnot, Ph.D.*
Director
Antiviral Gene Therapy Research Unit
University of the Witwatersrand

Dan Barouch, M.D., Ph.D.*
Professor
Ragon Institute of MGH, MIT and Harvard
Beth Israel Deaconess Medical Center

Jeffrey Bartlett, Ph.D.*
Chief Scientific Officer
Senior Vice President, Research and Development
Calimmune, Inc.

Michael Betts, Ph.D.*
Associate Professor
Department of Microbiology
Perelman School of Medicine
University of Pennsylvania

Tony Boitano, Ph.D.*
Vice President of Stem Cell Biology
Magenta Therapeutics

Eli Boritz, M.D., Ph.D.*
Chief, Virus Persistence and Dynamics Section
Vaccine Research Center
National Institute of Allergy and Infectious Diseases
National Institutes of Health

Alberto Bosque, Ph.D.*
Assistant Professor
Department of Microbiology, Immunology, and Tropical Medicine
The George Washington University

Jason Brechley, Ph.D.*
Senior Investigator
Immunopathogenesis Section
National Institute of Allergy and Infectious Diseases
National Institutes of Health

Dennis R. Burton, Ph.D.
Professor
Department of Immunology
The Scripps Research Institute

Shilpa Buch, Ph.D.*
Professor
Department of Pharmacology and Experimental Neuroscience
University of Nebraska Medical Center

Christian Buchholz, Ph.D.*
Head of Section
Molecular Biotechnology and Gene Therapy
Paul-Ehrlich-Institut

Salvatore T. Butera, D.V.M., Ph.D.
Chief Science Officer
Scripps CHAVI-ID
The Scripps Research Institute

Edward Campbell, Ph.D.
Assistant Professor
Department of Microbiology and Immunology
School of Medicine
Loyola University at Chicago

Toni Cathomen, Ph.D.*
Professor, Center for Chronic Immunodeficiency
Director, Institute for Cell and Gene Therapy
University Medical Center Freiburg

Alex Carballo-Dieguez, Ph.D.
Co-Director and Senior Research Scientist
HIV Center for Clinical and Behavioral Studies
New York State Psychiatric Institute
Columbia University

Ann Chahroudi, M.D., Ph.D.*
Associate Director, Clinical Affairs
School of Medicine
Emory University

***Nicolas Chomont, Ph.D.**
Assistant Professor
Microbiology and Immunology
Université de Montréal, Centre de Recherche du CHUM

David B. Clifford, M.D.
Professor
Department of Neurology
Washington University School of Medicine

C. Budd Colby, Ph.D.
Principal
Colby Biomedical Ventures

Grant Colfax, M.D.
Director
Marin Health and Human Services
San Rafael, California

Jessica Conway, Ph.D.*
Assistant Professor of Mathematics
The Huck Institutes of the Life Sciences
The Pennsylvania State University

Deborah Jean Cotton, M.D., M.P.H.
Professor of Medicine
Boston University School of Medicine

Bryan R. Cullen, Ph.D., D.Sc.
James B. Duke Professor
Department of Molecular Genetics and Microbiology
Director, Duke University Center for Virology
Duke University Medical Center

Susanna Cunningham-Rundles, Ph.D.
Professor Emerita of Research Immunology
Department of Pediatrics
Weill Cornell Medical College

Satya Dandekar, Ph.D.*
Professor and Chair
Department of Medical Microbiology and Immunology
University of California, Davis

Richard Thomas D'Aquila, M.D.
The Howard Taylor Ricketts Professor of Medicine
Division of Infectious Diseases
Director, Northwestern HIV Translational Research Center
Feinberg School of Medicine
Northwestern University

Steven Deeks, M.D.*
Professor
Department of Medicine
University of California, San Francisco

Bruno De Geest, Ph.D.
Chemical Engineer
Laboratory of Pharmaceutical Technology
Ghent University Hospital

Sherry Deren, Ph.D.
Co-Director
Center for Drug Use and HIV Research
New York University College of Nursing

Roger Detels, M.D., M.S.
Professor of Epidemiology
School of Public Health
University of California, Los Angeles

Carl W. Dieffenbach, Ph.D.
Director
Division of AIDS (DAIDS)
National Institute of Allergy and Infectious Diseases
National Institutes of Health

David DiGiusto, Ph.D.*
Executive Director of Stem Cell and Cellular Therapeutic Operations
Senior Academic Researcher in the Division of Stem Cell Transplantation and Regenerative Medicine
Stanford University

Robert W. Doms, M.D., Ph.D.*
Professor of Pathology and Laboratory Medicine
Department of Pathology and Laboratory Medicine
University of Pennsylvania

D. Peter Drotman, M.D., M.P.H.
Editor-in-Chief
Emerging Infectious Diseases
Centers for Disease Control and Prevention

Anke A. Ehrhardt, Ph.D.
Director
Division of Gender, Sexuality, & Health
Program for the Study of LGBT Health
NYS Psychiatric Institute/Columbia University

Homayoon Farzadegan, Ph.D.
Professor
Department of Epidemiology
Johns Hopkins Bloomberg School of Public Health

Michael Farzan, Ph.D.*
Vice Chairman and Professor
Department of Immunology and Microbial Science,
Florida Campus
The Scripps Research Institute

Dianne M. Finkelstein, Ph.D.
Professor of Biostatistics
Harvard School of Public Health
Director of the Cancer Center Biostatistics
Massachusetts General Hospital

Andrés Finzi, Ph.D.*
Associate Professor
Department of Microbiology and Immunology
Université de Montréal, Centre de Recherche du
CHUM

Gerald Herbert Friedland, M.D.
Professor and Director
AIDS Care Program
Department of Internal Medicine
Yale School of Medicine

Rémi Fromentin, Pharm.D., Ph.D.*
Postdoctoral Researcher
Université de Montréal, Centre de Recherche du
CHUM

Rajesh Gandhi, M.D.*
Director, HIV Clinical Services and Education
Massachusetts General Hospital

Nilu Goonetilleke, Ph.D.*
Assistant Professor
Department of Microbiology & Immunology
The University of North Carolina at Chapel Hill

Howard E. Gendelman, M.D.
Professor and Chair, Department of Pharmacology
and Experimental Neuroscience
Margaret R. Larson Professor of Internal Medicine
and Infectious Diseases
Director, Center for Neurodegenerative Disorders
University of Nebraska Medical Center

Warner Greene, M.D., Ph.D.*
Professor
Director and Senior Investigator, Center for HIV
Cure Research
Gladstone Institutes

Nancy L. Haigwood, Ph.D.
Director and Senior Scientist
Division of Pathobiology and Immunology
Oregon National Primate Research Center
Oregon Health and Science University

Brendan Harley, Ph.D.*
Associate Professor and Robert W. Schaefer
Faculty Scholar
Department of Chemical & Biomolecular
Engineering
University of Illinois

Daria Hazuda, Ph.D.*
Vice President, Infectious Diseases Discovery
and Chief Scientific Officer
MRL Cambridge Exploratory Science Center
Merck & Co., Inc.

Frederick Hecht, M.D.*
Professor
Department of Medicine
University of California, San Francisco

Andrew Henderson, Ph.D.*
Associate Professor
School of Medicine
Boston University

Timothy Henrich, M.D.*
Assistant Professor of Medicine
Division of Infectious Disease
University of California, San Francisco

Charles H. Hinkin, Ph.D.
Professor
Department of Psychiatry and Biobehavioral
Sciences
David Geffen School of Medicine
University of California, Los Angeles

Catarina Hioe, Ph.D.*
Professor
Medicine, Infectious Diseases, and Microbiology
Icahn School of Medicine at Mount Sinai

David Ho, M.D.
Scientific Director, Chief Executive Officer
Aaron Diamond AIDS Research Center

Thomas J. Hope, Ph.D.
Professor
Department of Cell and Molecular Biology
Feinberg School of Medicine
Northwestern University

Bonnie Howell, Ph.D.*
Executive Director, Infectious Disease and
Vaccines
Merck & Co., Inc.

Shiu-Lok Hu, Ph.D.
Professor
School of Pharmacy
University of Washington

Judd Hultquist, Ph.D.*
Postdoctoral Scholar
Gladstone Institutes

Peter Hunt, M.D.*
Associate Professor
Department of Medicine
University of California, San Francisco

Gero Hütter, M.D., Ph.D.*
Medical Director, Cellex

R. Paul Johnson, M.D.*
Professor of Medicine
Director, Yerkes National Primate Research Center
Emory University

Brad Jones, Ph.D.*
Assistant Professor
Microbiology, Immunology & Tropical Medicine
The George Washington University

Stephen Kaminsky, Ph.D.*
Associate Director, Belfer Gene Therapy
Core Facility
Professor of Research in Genetic Medicine
Department of Genetic Medicine
Weill Medical College of Cornell University

Jonathan Karn, Ph.D.*
Director
Center for AIDS Research
Case Western Reserve University

Fatah Kashanchi, Ph.D.*
Professor
National Center for Biodefense and Infectious
Disease
George Mason University

Daniel Kaufmann, M.D.*
Associate Professor
Department of Medicine
Université de Montréal, Centre de Recherche du
CHUM

Brandon Keele, Ph.D.*
Principal Investigator / Senior Principal Scientist
Frederick National Laboratory for Cancer Research
National Cancer Institute

Vineet KewalRamani, Ph.D.
Chief, Model Development Section
HIV Drug Resistance Program
National Cancer Institute
National Institutes of Health

Sanggu Kim, Ph.D.*
Assistant Professor
Department of Veterinary Biosciences
The Ohio State University

Scott Kitchen, Ph.D.
Assistant Professor of Medicine
Division of Hematology and Oncology
David Geffen School of Medicine
University of California, Los Angeles

Nicole Klatt, Ph.D.*
Assistant Professor
Department of Pharmaceutics
School of Pharmacy
University of Miami, School of Medicine

Richard Kornbluth, M.D., Ph.D.
President and Chief Scientific Officer
Multimeric Biotherapeutics, Inc.

Richard A. Koup, M.D.
Deputy Director, Vaccine Research Center
Chief, Immunology Laboratory
National Institute of Allergy and Infectious
Diseases
National Institutes of Health

Smita Kulkarni, Ph.D.*
Assistant Scientist
Department of Genetics
Texas Biomedical Research Institute

Priti Kumar, Ph.D.*
Associate Professor
Department of Infectious Diseases
Yale University

Daniel Kuritzkes, M.D.*
Harriet Ryan Albee Professor of Medicine
Department of Medicine
Brigham and Women's Hospital

Nathaniel R. Landau, Ph.D.
Professor
Department of Microbiology
New York University School of Medicine

Alan L. Landay, Ph.D.
Professor and Chairman
Department of Immunology and Microbiology
Rush-Presbyterian-St. Luke's Medical Center

Michael Lederman, M.D.
Scott R. Inkley Professor of Medicine
Associate Director, Center for AIDS Research
Case Western Reserve University

Tun-Hou Lee, D.Sc.
Professor of Virology, Emeritus
Department of Immunology and Infectious
Diseases
Harvard School of Public Health

Michael J. Leibowitz, M.D., Ph.D.
Professor, Medical Microbiology and Immunology
University of California, Davis

Kam W. Leong, Ph.D.*
Samuel Y. Sheng Professor of Biomedical
Engineering
Department of Biomedical Engineering
Columbia University

Robert J. Levine, M.D.
Professor of Medicine
Center for Interdisciplinary Research on AIDS
Yale University

Sharon Lewin, F.R.A.C.P., Ph.D.*
Director
Peter Doherty Institute for Infection and Immunity
University of Melbourne

Mathias Lichterfeld, M.D.*
Assistant Professor of Medicine
Massachusetts General Hospital

Judy Lieberman, M.D., Ph.D.
Senior Investigator
Immune Disease Institute
Professor of Pediatrics
Harvard Medical School

David Looney, M.D.*
Associate Professor of Medicine of Residence
Director, UCSD Center for AIDS Research
Molecular Biology Core
Medical Director of the San Diego VA Healthcare
System AIDS Care activity
Director, Microbiology Laboratory
VA San Diego Healthcare System
University of California San Diego

H. Kim Lyster, M.D.
Professor in Surgery, Immunology, Pathology
George Barth Geller Chair of Cancer Research
Director of the Center of Applied Therapeutics
Duke Cancer Institute
Duke University Medical Center

Rebecca Lynch, Ph.D.*
Assistant Professor
School of Medicine and Health Sciences
The George Washington University

Frank Maldarelli, M.D., Ph.D.
Investigator
HIV DRP Host-Virus Interaction Branch
National Cancer Institute
National Institutes of Health

David M. Margolis, M.D.
Professor of Medicine, Microbiology,
Immunology, and Epidemiology
School of Medicine
University of North Carolina at Chapel Hill

Martin H. Markowitz, M.D.
Professor and Clinical Director
Aaron Diamond AIDS Research Center

Javier Martinez-Picado, Ph.D.*
ICREA Research Professor
Life and Medical Sciences
AIDS Research Institute irsiCaixa and UVic-UCC

Fulvio Mavilio, Ph.D.*
Scientific Director
Genethon

Kenneth Hugh Mayer, M.D.
Infectious Disease Attending & Director of HIV
Prevention Research
Beth Israel Deaconess Medical Center
Professor of Medicine
Harvard Medical School
Medical Research Director, Co-Chair
The Fenway Institute/Fenway Health

Joseph M. McCune, M.D., Ph.D.
Professor of Medicine
Department of Medicine
University of California, San Francisco

Adrian McDermott, M.Sc., Ph.D.*
Chief, Vaccine Immunology Program
Vaccine Research Center
National Institute of Allergy and Infectious
Diseases
National Institutes of Health

David McDonald, Ph.D.*
Assistant Professor
Department of Molecular Biology and Microbiology
Case Western Reserve University

Donna Mildvan, M.D.
Chief, Division of Infectious Diseases
Department of Medicine
Beth Israel Medical Center

Jacob Giehm Mikkelsen, Ph.D.*
Professor
Department of Biomedicine
Aarhus University

Avindra Nath, M.D.*
Senior Investigator
Section of Infections of the Nervous System
National Institute of Neurological Diseases
and Stroke
National Institutes of Health

Jay A. Nelson, Ph.D.
Professor and Director
Vaccine and Gene Therapy Institute
Oregon Health and Science University

Una O'Doherty, M.D., Ph.D.*
Associate Professor
Department of Pathology and Laboratory Medicine
Perelman School of Medicine
University of Pennsylvania

Melanie Ott, M.D., Ph.D.*
Professor
Department of Medicine
University of California, San Francisco

Nancy Padian, Ph.D., M.P.H.
Adjunct Professor of Epidemiology
School of Public Health
University of California, Berkeley

Savita Pahwa, M.D.
Professor of Microbiology and Immunology
Professor in Pediatrics and Medicine
Director of the Miami Center for AIDS Research
University of Miami Leonard M. Miller School of
Medicine

Tristram G. Parslow, M.D., Ph.D.
William Patterson Timmie Professor and Chair
Department of Pathology and Laboratory Medicine
Emory University School of Medicine

Matija Peterlin, M.D.
Professor of Medicine, Microbiology and
Immunology
Department of Medicine
University of California, San Francisco

Sudheesh Pilakka Kanthikeel, Ph.D.*
Assistant Professor
Department of Immunology
Florida International University

Vicente Planelles, Ph.D.*
Professor
Department of Pathology
University of Utah

Vinayaka Prasad, Ph.D.*
Professor
Department of Microbiology and Immunology
Albert Einstein College of Medicine

Lynn Pulliam, Ph.D.
Professor
Department of Laboratory Medicine and Medicine
University of California, San Francisco
Veterans Affairs Medical Center

Jay Rappaport, Ph.D.*
Professor and Associate Chair
Department of Neuroscience
Temple University

Lee Ratner, M.D., Ph.D.
Professor
Department of Medicine
Washington University School of Medicine

Roger Keith Reeves, Ph.D.*
Assistant Professor in Medicine
Center for Virology and Vaccine Research
Beth Israel Deaconess Medical Center

Andrew Rice, Ph.D.
Professor
Department of Molecular Virology
and Microbiology
Baylor College of Medicine

Melissa Robbiani, Ph.D.
Senior Scientist and Director of Biomedical HIV
Research
Center for Biomedical Research
Population Council

Fabio Romerio, Ph.D.*
Assistant Professor
Department of Medicine
Institute of Human Virology
University of Maryland

Jean-Pierre Routy, M.D.*

Professor
Division of Experimental Medicine
Department of Medicine
McGill University

Ruth M. Ruprecht, M.D., Ph.D.

Scientist, Department of Virology and Immunology
Southwest National Primate Research Center
Director, Texas Biomed AIDS Research Program
Texas Biomedical Research Institute

Rachel Rutishauser, M.D., Ph.D.*

Assistant Adjunct Professor
Department of Medicine
University of California, San Francisco

Jonah Sacha, Ph.D.*

Assistant Professor
Vaccine and Gene Therapy Institute
Oregon National Primate Research Center
Oregon Health and Science University

Karl Salzwedel, Ph.D.*

Chief, Pathogenesis and Basic Research Branch
National Institute of Allergy and Infectious Diseases
National Institutes of Health

Shomyseh Sanjabi, Ph.D.*

Assistant Investigator
Gladstone Institute for Virology and Immunology
Gladstone Institute

Timothy Schacker, M.D.*

Professor of Medicine
Division of Infectious Disease and International Medicine
Department of Medicine
University of Minnesota

Frederick A. Schmitt, Ph.D.

Professor
Departments of Neurology, Psychiatry, and Psychology and Behavioral Science
Sanders Brown Center on Aging
University of Kentucky

Gerald Schochetman, Ph.D.

Senior Director
Diagnostics Research
Abbott Laboratories

Olivier Schwartz, Ph.D.*

Head
Department of Virology
Institut Pasteur

Eileen Scully, M.D., Ph.D.*

Assistant Professor of Medicine
School of Medicine
Johns Hopkins University

Janet Siliciano, Ph.D.*

Associate Professor of Medicine
School of Medicine
Johns Hopkins University

Guido Silvestri, M.D.*

Professor
School of Medicine
Yerkes National Primate Research Center
Emory University

Viviana Simon, M.D., Ph.D.*

Professor of Microbiology and Medicine
Department of Microbiology and Medicine
School of Medicine
Icahn School of Medicine at Mount Sinai

Gail Skowron, M.D.

Professor of Medicine
Boston University School of Medicine

Ole Schmeltz Søgaard, M.D., Ph.D.*

Associate Professor
Department of Infectious Diseases
Aarhus University Hospital

Nikunj Somia, Ph.D.*

Associate Professor
Department of Genetics, Cell Biology, and Development
College of Biological Sciences
University of Minnesota

Leonidas Stamatatos, Ph.D.

Member
Fred Hutchinson Cancer Research Center
Vaccine and Infectious Disease Division
Immunology and Vaccine Development Program
Seattle, WA

Kathryn Stephenson, M.D.*

Instructor in Medicine
Infectious Disease Division
Center for Virology and Vaccine Research
Beth Israel Deaconess Medical Center

Mario Stevenson, Ph.D.

Professor of Medicine
Chief, Division of Infectious Diseases
University of Miami Leonard M. Miller School of Medicine

Jonathan Stoye, Ph.D.*

Senior Group Leader
Retrovirus-host Interactions Laboratory
The Francis Crick Institute

Semih Tareen, Ph.D.*

Director
Juno Therapeutics

Saba Valadkhan, M.D., Ph.D.*

Assistant Professor
Department of Biochemistry
Case Western Reserve University

Susana Valente, Ph.D.*

Associate Professor
Department of Immunology and Microbial Sciences
The Scripps Research Institute

Barbara Visscher, M.D., Dr.P.H.

Professor of Epidemiology
University of California, Los Angeles

David Vlahov, Ph.D., R.N.

Professor of Nursing,
Epidemiology, and Biostatistics
University of California, San Francisco

David J. Volsky, Ph.D.

Professor of Medicine and Pathology
Icahn School of Medicine at Mount Sinai
Director of Molecular Virology Laboratory
Department of Medicine
Mount Sinai St. Luke's and Roosevelt Hospitals

John Wagner, M.D.*

Executive Medical Director, BMT Program,
University of Minnesota Masonic Children's Hospital
Professor, Department of Pediatrics
Pediatric Blood & Marrow Transplantation Center
University of Minnesota

Thor Wagner, M.D.*

Assistant Professor
Department of Infectious Disease
Seattle Children's Research Institute

Mark Wainberg, Ph.D.*

Professor
Lady Davis Institute for Medical Research
Jewish General Hospital
McGill University

Marc Weinberg, Ph.D.*

Assistant Professor Adjunct
Department of Molecular Medicine
The Scripps Research Institute, California Campus

Steven S. Witkin, Ph.D.

Professor of Immunology
Department of Obstetrics and Gynecology
Weill Cornell Medical College

Peter R. Wolfe, M.D.

Associate Clinical Professor
David Geffen School of Medicine
University of California, Los Angeles
Sub-Investigator
Ruane Clinical Research

Richard T. Wyatt, Ph.D.

Professor of Immunology
IAVI Center for Neutralizing Antibodies
The Scripps Research Institute

Steven Yuki, M.D.*

Assistant Professor
Department of Medicine
University of California, San Francisco

PROGRAM ADVISORY COUNCIL

Mervyn F. Silverman, M.D., M.P.H. (Chairman)

President
Mervyn F. Silverman Associates
Crockett, CA

Judith D. Auerbach, Ph.D.

Science and Policy Consultant, and Professor
School of Medicine
University of California, San Francisco

David Bloom, Ph.D.

Clarence James Gamble Professor of Economics and Demography
Department of Global Health and Population
Harvard T.H. Chan School of Public Health
Boston, MA

Tim Brown, Ph.D.

Senior Fellow
The East-West Center
Honolulu, HI

Daniel Douek, M.D., Ph.D.

Chief, Human Immunology Section
Vaccine Research Center
National Institute of Allergy and Infectious Diseases
National Institutes of Health

Daria J. Hazuda, Ph.D.

Vice President, Scientific Affairs for Infectious Disease
Merck & Company, Inc.
West Point, PA

Katherine Luzuriaga, M.D.

Professor, Molecular Medicine, Pediatrics and
Medicine
University of Massachusetts Medical School
Worcester, MA

Kenneth H. Mayer, M.D.

Infectious Disease Attending and
Director of HIV Prevention Research
Beth Israel Deaconess Medical Center

Professor of Medicine
Harvard Medical School

Medical Research Director and Co-Chair
The Fenway Institute/Fenway Health

Jeffrey L. Sturchio, Ph.D.

President and Chief Executive Officer
Rabin Martin, NYC

Visiting Scholar
The Institute for Applied Economics, Global Health
and the Study of Business Enterprise
Johns Hopkins University

Member
The Council on Foreign Relations

Phill Wilson

Chief Executive Officer and President
The Black AIDS Institute
Los Angeles, CA

MANAGEMENT GROUP

Kevin Robert Frost

Chief Executive Officer

Anthony Ancona

Vice President and Director, Human Resources

Susan J. Blumenthal, M.D., M.P.A.

Senior Policy and Medical Advisor

Bradley Jensen

Chief Financial Officer

Rowena Johnston, Ph.D.

Vice President and Director, Research

Jeffrey Laurence, M.D.

Senior Scientific Consultant for Programs

John F. Logan, Ph.D., J.D.

Vice President and General Counsel

Gregorio Millett, M.P.H.

Vice President and Director, Public Policy

Eric Muscatell

Vice President, Development

AnnMari Shannahan

Vice President, Public Information

Annette Sohn, M.D.

Vice President and Director, TREAT Asia

amfAR, The Foundation for AIDS Research

NEW YORK

120 Wall Street, 13th Floor
New York, NY 10005-3908
(212) 806-1600 (tel)
(212) 806-1601 (fax)

WASHINGTON, D.C.

1100 Vermont Avenue, NW
Suite 600
Washington, DC 20005
(202) 331-8600 (tel)
(202) 331-8606 (fax)

BANGKOK, THAILAND

TREAT Asia
Exchange Tower
388 Sukhumvit Road, Suite 2104
Klongtoey, Bangkok 10110
Thailand
+66 (0)2 663 7561 (tel)
+66 (0)2 663 7562 (fax)

www.amfar.org



bbb.org/charity

amfAR meets the BBB
Wise Giving Alliance's
Standards for Charity
Accountability.



★★★★
CHARITY NAVIGATOR
Four Star Charity



COMMUNITY
HEALTH CHARITIES